组蛋白去乙酰化酶抑制剂和去甲基化剂：用于癌症治疗的组蛋白去乙酰化酶抑制剂的临床开发

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.

作者信息

Piekarz Richard L, Sackett Dan L, Bates Susan E

机构信息

Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1903, USA.

出版信息

Cancer J. 2007 Jan-Feb;13(1):30-9. doi: 10.1097/PPO.0b013e31803c73cc.

DOI:10.1097/PPO.0b013e31803c73cc

PMID:17464244

Abstract

The histone deacetylase inhibitors are a new class of agents that are currently in various stages of clinical development. Clinical trials have demonstrated activity, urging further investigation. At the same time, it has been discovered that these agents have their own challenges. In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents.

摘要

组蛋白去乙酰化酶抑制剂是一类新型药物，目前正处于临床开发的各个阶段。临床试验已证明其有效性，促使进一步研究。与此同时，人们发现这些药物也有自身的挑战。在本综述中，我们讨论了迄今收集到的临床数据、旨在提高疗效的联合疗法以及这类新型药物的毒性。